LIFECORE BIOMEDICAL INC DE
For the period ended Aug 25, 2024. Filed Oct 4, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Aug 25, 2024 · Filed Oct 4, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Income Taxes
- Income Taxes
The provision for income taxes from continuing operations for the three months ended August 25, 2024 and August 27, 2023, was a benefit of $25 and an expense of $88, respectively. The effective tax rate for the three months ended August 25, 2024 and August 27, 2023 was 0.2% and (0.7)%, respectively. The effective tax rate for the three months ended August 25, 2024 and August 27, 2023, was lower than the statutory federal income tax rate of 21% primarily due to the valuation allowance recorded against certain deferred tax assets, offset by the federal and state research and development tax credits.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.